Breast Cancer | Specialty

Update from the National Consortium of Breast Centers

April 14th 2011

I have just returned from the 21st Interdisciplinary Conference of the National Consortium of Breast Centers

Taking Measures to Prevent Breast Cancer

April 5th 2011

A team of researchers explored the use of drugs in terms of breast cancer prevention strategies

Screening Breast Cancer Survivors: Do Mammograms work?

April 4th 2011

Evidence that surveillance by mammogram in breast cancer survivors has been lacking until now

Rocky Ride for Iniparib Not Yet Over

April 1st 2011

Iniparib remains an intriguing therapeutic possibility despite failing to meet its phase III primary endpoints

Dr. Twelves on the Value of the Iniparib Trial Results

April 1st 2011

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Dr. Twelves on Negative Phase III Iniparib Announcements

April 1st 2011

Dr. Twelves Describes Iniparib Clinical Trials

April 1st 2011

Follow Up Treatment With Tamoxifen

March 29th 2011

Tamoxifen, a common drug used to treat breast cancer, works by blocking the effect of estrogen on tumor cells.

Barriers to Mammogram Completion Persist Despite Insurance Coverage and Reminder Programs

March 28th 2011

New research suggested that concern about pain may deter obese women from undergoing mammography, while a busy schedule may dissuade women aged less than 60 years

March 2011 OncLive Checkup

March 25th 2011

Editors' picks for this month's best Websites, news, resources, and online information for oncologists.

Insured Women Are Skipping Mammograms at High Rates

March 22nd 2011

About 40% of insured women in the United States are not undergoing screening mammography at least every 2 years in keeping with guidelines from the USPSTF.

NCCN 2011 Guidelines for Breast Cancer: Yes on Avastin, No on CYP2D6

March 21st 2011

As the Avastin (bevacizumab) drama continues at the FDA, the National Comprehensive Cancer Network (NCCN) has weighed in.

Dr. Pearlstone on Ongoing Research in Breast Cancer

March 16th 2011

David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center, on important research taking place in the field of breast oncology.

The Final Word on CYP2D6 Testing and Tamoxifen?

March 16th 2011

CYP2D6 phenotype status does not predict tamoxifen efficacy in patients with early-stage breast cancer, according to a retrospective analysis of data from the Breast International Group

Shedding More Light on Identifying HER2

March 16th 2011

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

March 15th 2011

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Exercise, Weight-Lifting Help in Preventing Lymphedema

March 15th 2011

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

Dr. Tripathy on Bone Health in Breast Cancer Patients

March 15th 2011

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.

Dr. Tripathy Discusses Bisphosphonate Studies

March 15th 2011

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer.

Dr. Pearlstone on Biomarker Testing in the Community

March 14th 2011

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting